Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 67Cyclophosphamide 52fludarabine phosphate 44Whole-Body Irradiation 36Mycophenolic Acid 33Peripheral Blood Stem Cell Transplantation 29Tacrolimus 27Busulfan 24Cyclosporine 21Antilymphocyte Serum 21Melphalan 18Filgrastim 16Etoposide 15Methotrexate 14Radiotherapy 12Lenalidomide 12Cord Blood Stem Cell Transplantation 12fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10Dexamethasone 9Bendamustine Hydrochloride 9Prednisone 8Bortezomib 8thymoglobulin 7idelalisib 7Flow Cytometry 7Calcium Dobesilate 7ibritumomab tiuxetan 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell, Marginal Zone × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡